Watthanasuntorn Kanramon, Abid Haisam, Gnanajothy Rosana
Internal Medicine, Bassett Healthcare Network.
Hematology/Oncology, Bassett Healthcare Network.
BMJ Case Rep. 2018 Dec 13;11(1):e226727. doi: 10.1136/bcr-2018-226727.
Denosumab is a monoclonal antibody that has been widely used for the prevention of skeletal-related events in patients with cancer with solid tumours and bone metastases, and acts by reducing the release of calcium from bones into the bloodstream. Severe hypocalcaemia is a rare and dangerous side effect of denosumab. We present a case of a patient with metastatic prostate cancer who developed severe hypocalcaemia after receiving a single dose of denosumab. Further laboratory analysis showed that the patient had a low vitamin D level, which contributed to the development of hypocalcaemia. He required an inpatient admission for repeated doses of intravenous calcium.
地诺单抗是一种单克隆抗体，已被广泛用于预防患有实体瘤和骨转移的癌症患者发生骨相关事件，其作用机制是减少骨骼中的钙释放到血液中。严重低钙血症是地诺单抗一种罕见且危险的副作用。我们报告一例转移性前列腺癌患者，在接受单剂量地诺单抗后发生严重低钙血症。进一步的实验室分析显示该患者维生素D水平较低，这促成了低钙血症的发生。他需要住院接受多次静脉补钙治疗。
